Prospects for Pandemic Influenza Control with Currently Available Vaccines and Antivirals
Identifieur interne : 001E48 ( Istex/Corpus ); précédent : 001E47; suivant : 001E49Prospects for Pandemic Influenza Control with Currently Available Vaccines and Antivirals
Auteurs : Arnold S. MontoSource :
- Journal of Infectious Diseases [ 0022-1899 ] ; 1997.
Abstract
Since an influenza virus variant of pandemic potential may appear at any time, plans must be made to use currently available vaccines and antivirals most advantageously. Inactivated vaccines remain the principal intervention for the near future, and it can be assumed that quantities available at critical points in the epidemic will be limited unless advances are made in methods of vaccine production. Repeated demonstration of the effectiveness of vaccination of older persons in preventing hospitalization and death confirms that the traditional high-risk groups should be given priority. Since community transmission can be interrupted by vaccinating school-age children, this group may also be targeted. Antivirals in use and under development will almost certainly be active against the pandemic variant. Use during pandemics should be extensive but may be limited by the quantity of drugs available, the logistics of storage and distribution, and the possibility of side effects.
Url:
DOI: 10.1086/514172
Links to Exploration step
ISTEX:DC5D32D3640DFB11F803FE76AD23AF3E4B1A14F3Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Prospects for Pandemic Influenza Control with Currently Available Vaccines and Antivirals</title><author wicri:is="90%"><name sortKey="Monto, Arnold S" sort="Monto, Arnold S" uniqKey="Monto A" first="Arnold S." last="Monto">Arnold S. Monto</name><affiliation><mods:affiliation>Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:DC5D32D3640DFB11F803FE76AD23AF3E4B1A14F3</idno><date when="1997" year="1997">1997</date><idno type="doi">10.1086/514172</idno><idno type="url">https://api.istex.fr/ark:/67375/HXZ-R60NRS24-6/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001E48</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001E48</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Prospects for Pandemic Influenza Control with Currently Available Vaccines and Antivirals</title><author wicri:is="90%"><name sortKey="Monto, Arnold S" sort="Monto, Arnold S" uniqKey="Monto A" first="Arnold S." last="Monto">Arnold S. Monto</name><affiliation><mods:affiliation>Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Infectious Diseases</title><title level="j" type="abbrev">J Infect Dis.</title><idno type="ISSN">0022-1899</idno><idno type="eISSN">1537-6613</idno><imprint><publisher>The University of Chicago Press</publisher><date type="published">1997</date><biblScope unit="vol">176</biblScope><biblScope unit="issue">Supplemet_1</biblScope><biblScope unit="page" from="S32">S32</biblScope><biblScope unit="page" to="S37">S37</biblScope></imprint><idno type="ISSN">0022-1899</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-1899</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Since an influenza virus variant of pandemic potential may appear at any time, plans must be made to use currently available vaccines and antivirals most advantageously. Inactivated vaccines remain the principal intervention for the near future, and it can be assumed that quantities available at critical points in the epidemic will be limited unless advances are made in methods of vaccine production. Repeated demonstration of the effectiveness of vaccination of older persons in preventing hospitalization and death confirms that the traditional high-risk groups should be given priority. Since community transmission can be interrupted by vaccinating school-age children, this group may also be targeted. Antivirals in use and under development will almost certainly be active against the pandemic variant. Use during pandemics should be extensive but may be limited by the quantity of drugs available, the logistics of storage and distribution, and the possibility of side effects.</div></front></TEI><istex><corpusName>oup</corpusName><keywords><teeft><json:string>vaccine</json:string><json:string>antiviral</json:string><json:string>amantadine</json:string><json:string>monto</json:string><json:string>tecumseh</json:string><json:string>pandemic</json:string><json:string>vaccinated</json:string><json:string>rimantadine</json:string><json:string>prophylaxis</json:string><json:string>interpandemic</json:string><json:string>indirect protection</json:string><json:string>interpandemic period</json:string><json:string>pandemic control</json:string><json:string>school child</json:string><json:string>vaccination</json:string><json:string>respiratory condition</json:string><json:string>research question</json:string><json:string>illness rate</json:string><json:string>side effect</json:string><json:string>severe outcome</json:string><json:string>attenuated vaccine</json:string><json:string>older person</json:string><json:string>vaccine effectiveness</json:string><json:string>herd immunity</json:string><json:string>outbreak</json:string><json:string>hospitalization</json:string><json:string>public health</json:string><json:string>past experience</json:string><json:string>traditional group</json:string><json:string>second dose</json:string><json:string>peak period</json:string><json:string>more likely</json:string><json:string>monto table</json:string><json:string>recent study</json:string><json:string>pandemic period</json:string><json:string>population group</json:string><json:string>past pandemic</json:string><json:string>vaccine virus</json:string><json:string>respiratory illness</json:string><json:string>elderly person</json:string><json:string>available vaccine</json:string><json:string>initial priority</json:string><json:string>antiviral amantadine</json:string><json:string>individual basis</json:string><json:string>clinical illness</json:string><json:string>unvaccinated child</json:string><json:string>child vaccinated</json:string><json:string>tecumseh study</json:string><json:string>clinical trial</json:string><json:string>michigan student</json:string><json:string>clinical symptom</json:string><json:string>next pandemic</json:string><json:string>record system</json:string><json:string>pneumonia</json:string></teeft></keywords><author><json:item><name>Arnold S. Monto</name><affiliations><json:string>Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan</json:string></affiliations></json:item></author><arkIstex>ark:/67375/HXZ-R60NRS24-6</arkIstex><language><json:string>unknown</json:string></language><originalGenre><json:string>research-article</json:string></originalGenre><abstract>Since an influenza virus variant of pandemic potential may appear at any time, plans must be made to use currently available vaccines and antivirals most advantageously. Inactivated vaccines remain the principal intervention for the near future, and it can be assumed that quantities available at critical points in the epidemic will be limited unless advances are made in methods of vaccine production. Repeated demonstration of the effectiveness of vaccination of older persons in preventing hospitalization and death confirms that the traditional high-risk groups should be given priority. Since community transmission can be interrupted by vaccinating school-age children, this group may also be targeted. Antivirals in use and under development will almost certainly be active against the pandemic variant. Use during pandemics should be extensive but may be limited by the quantity of drugs available, the logistics of storage and distribution, and the possibility of side effects.</abstract><qualityIndicators><score>6.979</score><pdfWordCount>4560</pdfWordCount><pdfCharCount>26898</pdfCharCount><pdfVersion>1.4</pdfVersion><pdfPageCount>6</pdfPageCount><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><pdfWordsPerPage>760</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>false</refBibsNative><abstractWordCount>146</abstractWordCount><abstractCharCount>987</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>Prospects for Pandemic Influenza Control with Currently Available Vaccines and Antivirals</title><pmid><json:string>9240692</json:string></pmid><genre><json:string>research-article</json:string></genre><host><title>Journal of Infectious Diseases</title><language><json:string>unknown</json:string></language><issn><json:string>0022-1899</json:string></issn><eissn><json:string>1537-6613</json:string></eissn><publisherId><json:string>jid</json:string></publisherId><volume>176</volume><issue>Supplement-1</issue><pages><first>S32</first><last>S37</last></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>1981</json:string><json:string>1968</json:string><json:string>1997</json:string><json:string>06-30-97</json:string><json:string>1918</json:string><json:string>76S</json:string><json:string>1976</json:string><json:string>1977</json:string><json:string>1978</json:string></date><geogName></geogName><orgName><json:string>University of Michigan</json:string><json:string>University of Vermont</json:string><json:string>University of Chicago</json:string><json:string>University of Michigan School of Public Health</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Eli Lilly</json:string><json:string>Total</json:string></persName><placeName><json:string>Reactogenicity</json:string><json:string>United States</json:string><json:string>Ann Arbor</json:string><json:string>Hong Kong</json:string><json:string>Canada</json:string><json:string>Houston</json:string><json:string>Seattle</json:string><json:string>MI</json:string><json:string>Russia</json:string><json:string>Cleveland</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>[4]</json:string><json:string>[23]</json:string><json:string>[23, 24]</json:string><json:string>[6]</json:string><json:string>[22]</json:string><json:string>[8]</json:string><json:string>Fedson et al. [8]</json:string><json:string>Michigan, 1989</json:string><json:string>[5, 7]</json:string><json:string>[21]</json:string><json:string>Nichol et al. [9]</json:string><json:string>[20]</json:string><json:string>[1, 2]</json:string><json:string>[5]</json:string><json:string>Davenport et al. [3]</json:string><json:string>[25]</json:string><json:string>[9]</json:string><json:string>[13]</json:string><json:string>Dolin et al. [24]</json:string><json:string>[19]</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/HXZ-R60NRS24-6</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - microbiology</json:string><json:string>2 - infectious diseases</json:string><json:string>2 - immunology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - biomedical research</json:string><json:string>3 - microbiology</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Infectious Diseases</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Immunology and Allergy</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>1997</publicationDate><copyrightDate>1997</copyrightDate><doi><json:string>10.1086/514172</json:string></doi><id>DC5D32D3640DFB11F803FE76AD23AF3E4B1A14F3</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-R60NRS24-6/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-R60NRS24-6/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/HXZ-R60NRS24-6/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Prospects for Pandemic Influenza Control with Currently Available Vaccines and Antivirals</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>The University of Chicago Press</publisher><availability><licence>© 1997 by The University of Chicago</licence></availability><date type="Copyright" when="1997">1997</date><date type="published">1997</date></publicationStmt><notesStmt><note type="content-type" source="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="publication-type" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main">Prospects for Pandemic Influenza Control with Currently Available Vaccines and Antivirals</title><author xml:id="author-0000" role="corresp"><persName><surname>Monto</surname><forename type="first">Arnold S.</forename></persName><affiliation><address><addrLine>Ann Arbor</addrLine><addrLine>Michigan</addrLine></address></affiliation><affiliation role="corresp">Reprints or correspondence: Dr. Arnold S. Monto, University of Michigan School of Public Health, 109 Observatory, Ann Arbor, MI 48109.</affiliation></author><idno type="istex">DC5D32D3640DFB11F803FE76AD23AF3E4B1A14F3</idno><idno type="ark">ark:/67375/HXZ-R60NRS24-6</idno><idno type="DOI">10.1086/514172</idno></analytic><monogr><title level="j" type="main">Journal of Infectious Diseases</title><title level="j" type="abbrev">J Infect Dis.</title><idno type="hwp">jinfdis</idno><idno type="publisher-id">jid</idno><idno type="pISSN">0022-1899</idno><idno type="eISSN">1537-6613</idno><imprint><publisher>The University of Chicago Press</publisher><date type="published">1997</date><biblScope unit="vol">176</biblScope><biblScope unit="issue">Supplemet_1</biblScope><biblScope unit="page" from="S32">S32</biblScope><biblScope unit="page" to="S37">S37</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.46" when="2020-05-18"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract><p>Since an influenza virus variant of pandemic potential may appear at any time, plans must be made to use currently available vaccines and antivirals most advantageously. Inactivated vaccines remain the principal intervention for the near future, and it can be assumed that quantities available at critical points in the epidemic will be limited unless advances are made in methods of vaccine production. Repeated demonstration of the effectiveness of vaccination of older persons in preventing hospitalization and death confirms that the traditional high-risk groups should be given priority. Since community transmission can be interrupted by vaccinating school-age children, this group may also be targeted. Antivirals in use and under development will almost certainly be active against the pandemic variant. Use during pandemics should be extensive but may be limited by the quantity of drugs available, the logistics of storage and distribution, and the possibility of side effects.</p></abstract><textClass ana="subject"><keywords scheme="heading"><term>Articles</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc><revisionDesc><change when="2020-05-18" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-R60NRS24-6/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus oup, element #text not found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0"</istex:xmlDeclaration><istex:docType PUBLIC="-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" URI="journalpublishing.dtd" name="istex:docType"></istex:docType><istex:document><article article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="hwp">jinfdis</journal-id>
<journal-id journal-id-type="publisher-id">jid</journal-id>
<journal-title>Journal of Infectious Diseases</journal-title>
<abbrev-journal-title>J Infect Dis.</abbrev-journal-title>
<issn pub-type="ppub">0022-1899</issn>
<issn pub-type="epub">1537-6613</issn>
<publisher>
<publisher-name>The University of Chicago Press</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1086/514172</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Prospects for Pandemic Influenza Control with Currently Available Vaccines and Antivirals</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Monto</surname><given-names>Arnold S.</given-names></name><xref ref-type="corresp" rid="cor1"></xref>
</contrib>
<aff><italic>Department of Epidemiology, School of Public Health, University of Michigan</italic>, <addr-line>Ann Arbor, Michigan</addr-line></aff>
</contrib-group>
<author-notes>
<corresp id="cor1">Reprints or correspondence: Dr. Arnold S. Monto, University of Michigan School of Public Health, 109 Observatory, Ann Arbor, MI 48109.</corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>8</month>
<year>1997</year>
</pub-date>
<volume>176</volume>
<issue>Supplement_1</issue>
<fpage>S32</fpage>
<lpage>S37</lpage>
<copyright-statement>© 1997 by The University of Chicago</copyright-statement>
<copyright-year>1997</copyright-year>
<abstract>
<p>Since an influenza virus variant of pandemic potential may appear at any time, plans must be made to use currently available vaccines and antivirals most advantageously. Inactivated vaccines remain the principal intervention for the near future, and it can be assumed that quantities available at critical points in the epidemic will be limited unless advances are made in methods of vaccine production. Repeated demonstration of the effectiveness of vaccination of older persons in preventing hospitalization and death confirms that the traditional high-risk groups should be given priority. Since community transmission can be interrupted by vaccinating school-age children, this group may also be targeted. Antivirals in use and under development will almost certainly be active against the pandemic variant. Use during pandemics should be extensive but may be limited by the quantity of drugs available, the logistics of storage and distribution, and the possibility of side effects.</p>
</abstract>
</article-meta>
</front>
</article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Prospects for Pandemic Influenza Control with Currently Available Vaccines and Antivirals</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Prospects for Pandemic Influenza Control with Currently Available Vaccines and Antivirals</title></titleInfo><name type="personal"><namePart type="given">Arnold S.</namePart><namePart type="family">Monto</namePart><affiliation>Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan</affiliation></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="research-article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>The University of Chicago Press</publisher><dateIssued encoding="w3cdtf">1997-08</dateIssued><copyrightDate encoding="w3cdtf">1997</copyrightDate></originInfo><abstract>Since an influenza virus variant of pandemic potential may appear at any time, plans must be made to use currently available vaccines and antivirals most advantageously. Inactivated vaccines remain the principal intervention for the near future, and it can be assumed that quantities available at critical points in the epidemic will be limited unless advances are made in methods of vaccine production. Repeated demonstration of the effectiveness of vaccination of older persons in preventing hospitalization and death confirms that the traditional high-risk groups should be given priority. Since community transmission can be interrupted by vaccinating school-age children, this group may also be targeted. Antivirals in use and under development will almost certainly be active against the pandemic variant. Use during pandemics should be extensive but may be limited by the quantity of drugs available, the logistics of storage and distribution, and the possibility of side effects.</abstract><note type="author-notes">Reprints or correspondence: Dr. Arnold S. Monto, University of Michigan School of Public Health, 109 Observatory, Ann Arbor, MI 48109.</note><relatedItem type="host"><titleInfo><title>Journal of Infectious Diseases</title></titleInfo><titleInfo type="abbreviated"><title>J Infect Dis.</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">0022-1899</identifier><identifier type="eISSN">1537-6613</identifier><identifier type="PublisherID">jid</identifier><identifier type="PublisherID-hwp">jinfdis</identifier><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>176</number></detail><detail type="issue"><caption>no.</caption><number>Supplement-1</number></detail><extent unit="pages"><start>S32</start><end>S37</end></extent></part></relatedItem><identifier type="istex">DC5D32D3640DFB11F803FE76AD23AF3E4B1A14F3</identifier><identifier type="ark">ark:/67375/HXZ-R60NRS24-6</identifier><identifier type="DOI">10.1086/514172</identifier><accessCondition type="use and reproduction" contentType="copyright">© 1997 by The University of Chicago</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-GTWS0RDP-M">oup</recordContentSource><recordOrigin>Converted from (version 1.2.14) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2020-05-25</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-R60NRS24-6/record.json</uri></json:item></metadata><annexes><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-R60NRS24-6/annexes.pdf</uri></json:item></annexes><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E48 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001E48 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:DC5D32D3640DFB11F803FE76AD23AF3E4B1A14F3
|texte= Prospects for Pandemic Influenza Control with Currently Available Vaccines and Antivirals
}}
| This area was generated with Dilib version V0.6.34. |  |